PharmaShots | Incisive News in 3 Shots

Subscribe Now

Cabometyx

Takeda and Ono's Opdivo (nivolumab) + Cabometyx (cabozantinib) Receive MHLW's Approval for the Treatment of Unresectable or Metastatic Renal Cell Carcinoma

Takeda and Ono's Opdivo (nivolumab) + Cabometyx (cabozantinib) Receive MHLW's Approval for the Treatment of Unresectable or Metast...

August 25, 2021

PharmaShots Interview: Ipsen's Dr. Med. Steven Hildemann Shares Insight on the EC's Approval of Cabometyx + Nivolumab for Advanced Renal Cell Carcinoma

PharmaShots Interview: Ipsen's Dr. Med. Steven Hildemann Shares Insight on the EC's Approval of Cabometyx + Nivolumab for Advanced...

May 11, 2021

BMS' Opdivo (nivolumab) + Cabometyx (cabozantinib) Receive CHMP's Positive Opinion as 1L Treatment for Advanced Renal Cell Carcinoma

BMS' Opdivo (nivolumab) + Cabometyx (cabozantinib) Receive CHMP's Positive Opinion as 1L Treatment for Advanced Renal Cell Carcino...

March 1, 2021

Exelixis' Cabometyx (cabozantinib) Receives FDA Approval for Previously Treated Hepatocellular Carcinoma (HCC)

Exelixis' Cabometyx (cabozantinib) Receives FDA Approval for Previously Treated Hepatocellular Carcinoma (HCC)

January 15, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us